EYPT — EyePoint, Inc.
—
Nasdaq ·
Unknown ·
Unknown ·
CIK 1314102 ·
Last close
$13.35
Market Cap
$1.12B
52W High
$18.87
52W Low
$11.40
ADV30
829,335
Next earnings
—
Quarterly Fundamentals
Revenues vs Net Income (last 4 Q)
Assets vs Liabilities (last 4 Q)
| Period | Revenues | GrossProfit | OpIncome | NetIncome | Assets | Cash | Liabilities |
|---|---|---|---|---|---|---|---|
| Mar 2026 | 696,000 | 168,000 | -87,226,000 | -84,832,000 | 288,217,000 | 77,712,000 | 57,745,000 |
| Dec 2025 | 620,000 | 245,000 | -70,345,000 | -67,609,000 | 363,996,000 | 101,821,000 | 57,883,000 |
| Sep 2025 | 966,000 | 245,000 | -62,025,000 | -59,732,000 | 251,695,000 | 74,577,000 | 51,513,000 |
| Jun 2025 | 5,333,000 | 5,168,000 | -62,227,000 | -59,426,000 | 301,147,000 | 71,143,000 | 55,138,000 |
Cashflow TTM (yfinance, fills SEC gap)
Operating CF
$-240,110,000
Investing CF
$68,580,000
Financing CF
$173,647,000
CapEx
$-3,280,000
Dividends Paid
—
Buybacks
—
EPS Diluted TTM
$-3.16
As of
2026-05-10
Balance + Analyst (yfinance extras)
Retained Earnings
$-1,104,978,000
Inventory
$1,813,000
Receivables
$651,000
ST Investments
$204,265,000
EBIT TTM
$-231,650,000
Pretax Income TTM
$-231,683,000
Interest Exp TTM
$14,000
Analysts
12
Yahoo Snapshot (yfinance, live)
Total Revenue
$7,614,000
EBITDA
$-279,375,008
Free Cash Flow
$-168,724,992
Enterprise Value
$1,199,985,920
Total Cash
$45,261,000
Total Debt
$17,621,000
Shares Out
83,841,298
Trailing EPS
$-3.51
Book Value
$0.40
ROE
-102.7%
ROA
-54.1%
Div Yield
—
Annual Trend (SEC EDGAR, last 4y)
Revenues vs Net Income (last 4y)
| FY end | Revenues | OpIncome | NetIncome | Assets | Liabilities | Equity | OCF |
|---|---|---|---|---|---|---|---|
| Dec 2025 | 31,371,000 | -243,434,000 | -231,962,000 | 363,996,000 | 57,883,000 | — | -240,110,000 |
| Dec 2024 | 43,273,000 | -145,854,000 | -130,870,000 | 418,465,000 | 81,964,000 | — | -126,226,000 |
| Dec 2023 | 46,018,000 | -75,067,000 | -70,795,000 | 355,184,000 | 88,861,000 | — | 1,875,000 |
| Dec 2022 | 41,404,000 | -78,938,000 | -102,254,000 | 180,356,000 | 83,988,000 | — | -65,005,000 |
TTM Snapshot
Revenues TTM
—
NetIncome TTM
—
OpCashFlow TTM
—
Assets (Latest)
—
Forward EPS
$-2.82
Max Pain — expiry 2026-10-16
max pain strike: $17.50 · spot: $13.35 · call oi: 7,751 · put oi: 13,823
Expected Move to 2026-10-16:
±$12.10
(90.64%) —
implied range
$1.25 –
$25.45
· ATM straddle on $12.50 strike
News headlines (Yahoo Finance, 1h cache)
EyePoint Pharmaceuticals Eyes Transformative 2026 as DURAVYU Phase 3 Data Nears
2026-05-26 16:04 · Yahoo
How The EyePoint (EYPT) Narrative Is Evolving With DURAVYU Trials And New Analyst Targets
2026-05-21 05:13 · Yahoo
EyePoint Announces Participation at Upcoming Investor Conferences
2026-05-19 11:00 · Yahoo
EyePoint Reports Inducement Grants Under NASDAQ Listing Rule 5635(c)(4)
2026-05-18 11:00 · Yahoo
Alumis Stock Has Soared 400%. Cormorant Bought Another $8 Million Last Quarter
2026-05-17 18:33 · Yahoo
Erasca Stock Is Up 715%. Here’s Why One Biotech Fund Still Bought $68 Million More
2026-05-17 18:18 · Yahoo
Assessing EyePoint (EYPT) Valuation After Recent Share Price Weakness
2026-05-17 13:14 · Yahoo
EyePoint Announces Third Consecutive Positive DSMC Recommendation for Phase 3 Wet AMD Trials for DURAVYU™, Building Confidence Ahead of Mid-2026 Topline Data
2026-05-14 11:00 · Yahoo
EyePoint (EYPT) Q1 2026 Earnings Transcript
2026-05-07 15:51 · Yahoo
EyePoint Pharmaceuticals, Inc. Q1 2026 Earnings Call Summary
2026-05-07 12:30 · Yahoo
Recent Insider Activity
No insider activity indexed for this ticker.